机构投资者在Q2成果强劲和保持收入指导的情况下增加了对Vertex制药业的股权。 Institutional investors increased stakes in Vertex Pharmaceuticals amid strong Q2 results and maintained earnings guidance.

机构投资者增加了在问题2中Vertex制药公司的股权, Hanson & Doremus公司增加了200股,Alpine银行财富管理公司增加了53.3%。 Institutional investors increased their stakes in Vertex Pharmaceuticals in Q2, with Hanson & Doremus adding 200 shares and Alpine Bank Wealth Management boosting its position by 53.3%. 该公司报告Q2成绩强劲,每股收入4.52美元,收入增加11.3%,达29.4亿美元,并保持全年收入指导。 The company reported strong Q2 results, earning $4.52 per share, up 11.3% in revenue to $2.94 billion, and maintaining its full-year earnings guidance. 分析师认为该股票是"中等买入",目标价为493.81美元. Analysts rate the stock a "Moderate Buy" with a $493.81 target. 该股票于2025年9月29日以385.73美元开放,市场上限为989.9亿美元。 The stock opened at $385.73 on September 29, 2025, with a market cap of $98.90 billion.